A5026098786- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Laser-induced spectroscopy and plasma
- Atomic and Molecular Physics
- Hemoglobinopathies and Related Disorders
- Retinoids in leukemia and cellular processes
- Lymphoma Diagnosis and Treatment
- RNA modifications and cancer
- Cancer-related gene regulation
- X-ray Spectroscopy and Fluorescence Analysis
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- Histone Deacetylase Inhibitors Research
- Sarcoma Diagnosis and Treatment
- Hematological disorders and diagnostics
- Vascular Tumors and Angiosarcomas
- Immune cells in cancer
- Bone and Joint Diseases
- Kruppel-like factors research
- Acute Lymphoblastic Leukemia research
- HVDC Systems and Fault Protection
- Ocular and Laser Science Research
- Cold Atom Physics and Bose-Einstein Condensates
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Atmospheric Ozone and Climate
First Affiliated Hospital Zhejiang University
2019-2025
Zhejiang University
2009-2025
Zhejiang Cancer Hospital
2023
Blood Center of Zhejiang Province
2022
Jilin University
2011-2019
Mutant isocitrate dehydrogenases (IDHs) produce R-2-hydroxyglutarate (R-2HG), which inhibits the growth of most acute myeloid leukemia (AML) cells. Here, we showed that necroptosis, a form programmed cell death, contributed to antileukemia activity R-2HG. Mechanistically, R-2HG competitively inhibited lysine demethylase 2B (KDM2B), an α-ketoglutarate-dependent dioxygenase. KDM2B inhibition increased histone 3 4 trimethylation levels and promoted expression receptor-interacting protein kinase...
Molecular-clinical prognostic models for Myelodysplastic syndromes (MDS) offer more accurate prognosis predictions, yet existing often overlook the heterogeneity of mutational profiles against cytogenetic background. Moreover, how to apply these in regions where large panel NGS is unaffordable remains a significant challenge be addressed. A total 237 NK MDS patients from our center were used as training set screen key variables and develop model with overall survival (OS) endpoint. The...
ABSTRACT This study, including 412 patients newly diagnosed with myelodysplastic neoplasm (MDS), investigated the clinical, molecular, and prognostic features of MDS moderate‐to‐severe bone marrow fibrosis (MF). Among MDS, 347 (84%) had MF grade 0–1 (MF0–1), 65 (16%) 2–3 (MF2–3). Patients MF2–3 showed similar overall survival (OS) (16.6 vs. 21.3 months; p = 0.34) but demonstrated inferior progression‐free (PFS) (6.6 15.2 0.02) a higher risk leukemia transformation (35.4 16.4%; < 0.001)...
Abstract Patients with lower‐risk myelodysplastic syndromes (LR‐MDS) as defined by the International Prognostic Scoring System (IPSS) have more favorable prognosis in general, but significant inter‐individual heterogeneity exists. In this study, we examined molecular profile of 15 MDS‐relevant genes 159 patients LR‐MDS using next‐generation sequencing. univariate COX regression, shorter overall survival (OS) was associated mutation status ASXL1 ( P = .001), RUNX1 .031), EZH2 .049), TP53...
Decitabine (DAC) is used as the first-line therapy in patients with higher-risk myelodysplastic syndromes (HR-MDS) and elderly acute myeloid leukaemia (AML) unsuitable for intensive chemotherapy. However, clinical outcomes of treated DAC a monotherapy are far from satisfactory. Adding all-trans retinoic acid (ATRA) to reportedly benefitted MDS AML patients. underlying mechanisms remain unclear need further explorations laboratory experiments.We cell lines primary cells evaluate combined...
We propose a scheme for achieving phase-dependent coherent population trapping, showing that both the dark state of atoms and light propagation dynamics depend on relative phase fields. The atomic coherence prepared via adiabatic process plays key role in interaction with matter. And an optical switching based phase-controlled quantum interference is implemented, which may have potential application high-speed communications information systems.
Radiative lifetimes of 79 levels belonging to the 3d34s4p, 3d44p, 3d34s5p, 3d45p, and 3d34s4d configurations V i with energy from 26,604.807 46,862.786 cm−1 have been measured using time-resolved laser-induced fluorescence (TR-LIF) spectroscopy in laser-produced plasma. The lifetime values reported this paper are range 3.3–494 ns, uncertainties these measurements within ±10%. A good agreement was obtained previous data. HFR+CPOL calculations performed used combine calculated branching...
Abstract N6-methyladenosine (m 6 A) is the most prevalent epitranscriptomic modification in mammalian mRNA. Recent studies have revealed m A involved pathogenesis of various malignant tumors including hematologic neoplasms. Nevertheless, specific roles and regulators myelodysplastic neoplasms (MDS) remain poorly understood. Herein, we demonstrated that level expression methyltransferase METTL14 were elevated MDS patients with bone marrow blasts ≥5%. Additionally, upregulated as disease risk...
Abstract Purpose To explore the relevance of cytogenetic or molecular genetic abnormalities to clinical variables, including and laboratory characteristics prognosis in Chinese patients with myelodysplastic syndromes (MDS). Methods A total 634 consecutive diagnosed MDS at The First Affiliated Hospital, Zhejiang University School Medicine from June 2008 May 2018 were retrospectively included this study. All had evaluable analysis, 425 MDS‐related mutations sequencing. Results 38.6% displayed...
Objective: To analyze the percentage of myeloperoxidase (MPO)-positive acute myeloid leukemia (AML) blast cells, and to explore correlation MPO expression with clinical features, gene alterations, therapeutic response prognosis AML. Methods: The expressions in BM blasts cells 233 newly diagnosed AML were retrospectived analyzed, they divided into two groups using MPO-positive [low (≤70%) high (>70%)], chemotherapy efficacy compared between groups. Results: ①Of patients, 121(51.9%) low group,...
Abstract Chronic myelomonocytic leukemia (CMML) is a rare disease of elderly people characterized by the presence sustained peripheral blood monocytosis, overlapping features myeloproliferation, and myelodysplasia. We present large retrospective study 156 CMML patients in China. Mean age at diagnosis was 68 years old (range 23‐91). According to CMML‐specific prognostic scoring system (CPSS), 10 (8.3%) were low risk, 27 (22.5%) intermediate‐1 72 (60%) intermediate‐2 11 (9.2%) high risk. A...
According to 2008 WHO classification RARS is regarded as less than 5% blasts and more 15% ring sideroblasts in the bone marrow. In 2016 MDS-RS revised or presence of SF3B1 mutation. our study, we classified intracellular iron marrow into four types according size quantity granules. We found that there was a significant difference between SF3B1-mutant SF3B1-wild-type MDS patients III, IV sideroblasts. defined (III + RS)%×100 ‘Iron score’. suggest carrying mutation with Iron score ≥10 will...
Abstract Aim The aim of this study was to evaluate the clinical and molecular characteristics myelodysplastic syndrome (MDS) patients with monosomal karyotype (MK). Methods Eighty MDS MK diagnosed between January 2010 December 2018 were included in retrospective study. Seventy‐three had complex (CK) 46 very CK (vCK, ≥ 5 abnormalities). Clinical information collected, a panel 37 genes, on which mutations have been previously reported be associated patients, analyzed by next‐generation...
The treatment of patients with refractory and/or relapsed (R/R) high-risk myelodysplastic syndrome (HR-MDS) remains a daunting clinical challenge. Venetoclax is selective BCL-2 inhibitor, which combined hypomethylating agents (HMAs), increased responses and prolonged survival in unfit previously untreated acute myeloid leukemia. We performed retrospective study R/R HR-MDS receiving combination azacytidine (AZA) plus 15-days duration venetoclax (VEN-15d) order to determine their efficacy...